| 樊 菁,杨凤玲,王 霞,赵思嘉,田 刚.苯扎贝特片联合非洛地平缓释片对高血压合并血脂代谢紊乱患者血脂水平、内皮细胞功能及炎性细胞因子的影响[J].,2021,(13):2569-2573 |
| 苯扎贝特片联合非洛地平缓释片对高血压合并血脂代谢紊乱患者血脂水平、内皮细胞功能及炎性细胞因子的影响 |
| Effect of Bezafibrate Tablets Combined with Felodipine Sustained Release Tablets on Blood Lipid Levels, Endothelial Cell Function and Inflammatory Cytokines of Hypertension Patients with Dyslipidemia |
| 投稿时间：2021-01-20 修订日期：2021-02-15 |
| DOI：10.13241/j.cnki.pmb.2021.13.036 |
| 中文关键词: 高血压 血脂代谢紊乱 苯扎贝特片 非洛地平缓释片 疗效 |
| 英文关键词: Hypertension Dyslipidemia Bezafibrate tablets Felodipine sustained release tablets Efficacy |
| 基金项目:陕西省科学技术研究发展计划重点项目（2018ZDXM-SF-049） |
|
| 摘要点击次数: 720 |
| 全文下载次数: 470 |
| 中文摘要: |
| 摘要 目的：探讨苯扎贝特片联合非洛地平缓释片对高血压合并血脂代谢紊乱患者血脂水平、内皮细胞功能及炎性细胞因子的影响。方法：选择2018年1月到2020年1月我院收治的105例高血压合并血脂代谢紊乱患者，按随机表字法随机分为观察组（53例）和对照组（52例）。两组均予以调脂饮食，随后对照组给予非洛地平缓释片治疗，观察组给予苯扎贝特片联合非洛地平缓释片治疗。比较两组收缩压（SBP）、舒张压（DBP）、空腹血糖（GLU）、空腹胰岛素（FINS）、胰岛素抵抗指数（HOMA-IR）、总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白（HDL-C）、低密度脂蛋白（LDL-C）、白细胞介素-6（IL-6）、超敏C-反应蛋白（hs-CRP）、一氧化氮（NO）、内皮素（ET）、肿瘤坏死因子α（TNF-α）水平。结果：两组治疗后SBP、DBP、GLU、FINS、血清TG、TC、LDL-C、ET、TNF-α、IL-6、hs-CRP水平及HOMA-IR均明显低于治疗前（P<0.05），血清HDL-C、NO水平均高于治疗前（P<0.05），同时观察组治疗后SBP、DBP、GLU、FINS、血清TG、TC、LDL-C、ET、TNF-α、IL-6、hs-CRP水平及HOMA-IR低于对照组（P<0.05），血清HDL-C、NO水平均高于对照组（P<0.05）。结论：苯扎贝特片联合非洛地平缓释片能够更好地调节高血压合并血脂代谢紊乱患者的血压、血脂水平，改善血管内皮功能和胰岛素抵抗，降低血清炎症因子水平。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the effect of bezafibrate tablets combined with felodipine sustained release tablets on blood lipid levels, endothelial cell function and inflammatory cytokines of hypertension patients with dyslipidemia. Methods: According to the random indicator method, 105 cases of hypertension patients with dyslipidemia in our hospital from 2018 January to January 2020 were divided into the observation group(n=53) and the control group(n=52). Both groups were given a fat regulating diet, then control group was treated with felodipine sustained release tablets, observation group was treated with bezafibrate tablets combined with felodipine sustained release tablets. Compare the systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (GLU), triglyceride (TG), insulin resistance index (HOMA-IR), total cholesterol (TC), interleukin 6 (IL-6), low density lipoprotein (LDL-C), hypersensitive C-reactive protein (hs-CRP), fasting insulin (FINS), nitric oxide (NO), high density lipoprotein (HDL-C), endothelin (ET) and tumor necrosis factor α(TNF-α) levels of the two groups. Results: The SBP, DBP, GLU, FINS, serum TG, TC, LDL-C, ET, TNF-α, IL-6, hs-CRP levels and HOMA-IR of the two groups were significantly lower than before treatment(P<0.05), the serum HDL-C and NO of the two groups were higher than before treatment(P<0.05). Meanwhile, the SBP, DBP, GLU, FINS, serum TG, TC, LDL-C, ET, TNF-α, IL-6, hs-CRP levels and HOMA-IR of observation group were lower than those of control group(P<0.05), and serum HDL-C and NO levels were all higher than those of control group (P<0.05). Conclusion: The hypertension patients with dyslipidemia use bezafibrate tablets combined with felodipine sustained release tablets treat can adjust the blood pressure and blood lipid levels, improve vascular endothelial function and insulin resistance, reduce the serum levels of inflammatory factors. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
